Clinical Commissioning Policy: Ivacaftor for children aged 2 – 5 years with cystic fibrosis (named mutations)

Document first published:
Page updated:
Topic:
,
Publication type:
This document describes the evidence that has been considered by NHS England in formulating a policy to routinely commission Ivacaftor for children aged 2 – 5 years with cystic fibrosis.